[Skip to Content]
[Skip to Content Landing]
Article
October 1956

Amodiaquin (Camoquin) in the Treatment of Chronic Discoid Lupus ErythematosusPreliminary Report, with Special Reference to the Successful Response of Patients Resistant to Other Antimalarial Drugs

Author Affiliations

San Diego, Calif.; (MC), U.S.N.

From the private practice of Dr. R. B. pappenfort, and the Dermatology Service of Capt. James H. Lockwood (MC), U.S.N., U. S. Naval Hospital, San Diego, Calif.

AMA Arch Derm. 1956;74(4):384-386. doi:10.1001/archderm.1956.01550100052009
Abstract

Amodiaquin (Camoquin), first synthesized in 1946 by Burckhalter and associates,1 is one of the 4-aminoquinolines, a group of compounds discovered after the development of quinacrine (Atabrine). Extensive investigations in the period 1946 to 1954 with these compounds, particularly chloraquine and amodiaquin, firmly established their value in the suppressive treatment of vivax and falciparum malaria.2 The value of chloroquine and quinacrine in the treatment of discoid lupus erythematosus is well established and need not be reviewed.

Having almost simultaneously encountered two patients with chronic discoid lupus erythematosus who failed to respond to quinacrine and chloroquine therapy, we decided to try amodiaquin, since a small supply was available to one of us (R. B. P.) through a local pharmacy. The results in these and in subsequent patients were very gratifying, thus prompting this preliminary report.

Report of Cases

Case 1.—A 31-year-old white woman was

First Page Preview View Large
First page PDF preview
First page PDF preview
×